Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 251

1.

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility.

Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED.

Circulation. 2007 Jul 17;116(3):238-48. Epub 2007 Jul 2.

PMID:
17606845
2.

Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling.

Schäfer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H, Kast R, Klein M.

Cardiovasc Res. 2009 Apr 1;82(1):30-9. doi: 10.1093/cvr/cvp002. Epub 2009 Jan 8.

PMID:
19131365
4.

Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development.

Sanchez LS, de la Monte SM, Filippov G, Jones RC, Zapol WM, Bloch KD.

Pediatr Res. 1998 Feb;43(2):163-8.

PMID:
9475279
5.

Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells.

Wharton J, Strange JW, Møller GM, Growcott EJ, Ren X, Franklyn AP, Phillips SC, Wilkins MR.

Am J Respir Crit Care Med. 2005 Jul 1;172(1):105-13. Epub 2005 Apr 7.

PMID:
15817798
6.

Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5.

Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, Ketner EA, Moens AL, Champion HC, Kass DA.

Circulation. 2007 Apr 24;115(16):2159-67. Epub 2007 Apr 9. Erratum in: Circulation. 2007 May 22;115(20):e536.

PMID:
17420342
7.
8.

Low-dose phosphodiesterase inhibition improves responsiveness to inhaled nitric oxide in isolated lungs from endotoxemic rats.

Klein A, Zils U, Bopp C, Gries A, Martin E, Gust R.

J Surg Res. 2007 Apr;138(2):224-30. Epub 2007 Feb 1.

PMID:
17275845
9.

Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites.

Thiesson HC, Jensen BL, Jespersen B, Schaffalitzky de Muckadell OB, Bistrup C, Walter S, Ottosen PD, Veje A, Skøtt O.

Am J Physiol Renal Physiol. 2005 May;288(5):F1044-52. Epub 2004 Dec 21.

10.

Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure.

Stehlik J, Movsesian MA.

Expert Opin Investig Drugs. 2006 Jul;15(7):733-42. Review.

PMID:
16787138
11.

Profiling of cAMP and cGMP phosphodiesterases in isolated ventricular cardiomyocytes from human hearts: comparison with rat and guinea pig.

Johnson WB, Katugampola S, Able S, Napier C, Harding SE.

Life Sci. 2012 Feb 27;90(9-10):328-36. doi: 10.1016/j.lfs.2011.11.016. Epub 2012 Jan 10.

PMID:
22261303
12.
14.

Right ventricular cyclic nucleotide signaling is decreased in hyperoxia-induced pulmonary hypertension in neonatal mice.

Heilman RP, Lagoski MB, Lee KJ, Taylor JM, Kim GA, Berkelhamer SK, Steinhorn RH, Farrow KN.

Am J Physiol Heart Circ Physiol. 2015 Jun 15;308(12):H1575-82. doi: 10.1152/ajpheart.00569.2014. Epub 2015 Apr 10.

15.

Phosphodiesterase 5 and effects of sildenafil on cerebral arteries of man and guinea pig.

Kruuse C, Khurana TS, Rybalkin SD, Birk S, Engel U, Edvinsson L, Olesen J.

Eur J Pharmacol. 2005 Oct 3;521(1-3):105-14. Epub 2005 Sep 21.

PMID:
16182282
16.

Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5).

Salvi F, Sarzani R, Giorgi R, Donatelli G, Pietrucci F, Micheli A, Baldoni M, Minardi D, Dessì-Fulgheri P, Polito M, Muzzonigro G, Rappelli A.

Int J Impot Res. 2004 Oct;16(5):412-7. Erratum in: Int J Impot Res. 2006 Jul-Aug;18(4):414. Minaroli, D [corrected to Minardi, D].

PMID:
15175637
17.

Expression and functional activity of phosphodiesterase type 5 in human and rabbit vas deferens.

Mancina R, Filippi S, Marini M, Morelli A, Vignozzi L, Salonia A, Montorsi F, Mondaini N, Vannelli GB, Donati S, Lotti F, Forti G, Maggi M.

Mol Hum Reprod. 2005 Feb;11(2):107-15. Epub 2005 Jan 7.

PMID:
15640438
18.

Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeutical aspects.

Kulkarni SK, Patil CS.

Methods Find Exp Clin Pharmacol. 2004 Dec;26(10):789-99. Review.

PMID:
15672122
19.

Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor.

Vemulapalli S, Watkins RW, Chintala M, Davis H, Ahn HS, Fawzi A, Tulshian D, Chiu P, Chatterjee M, Lin CC, Sybertz EJ.

J Cardiovasc Pharmacol. 1996 Dec;28(6):862-9.

PMID:
8961086
20.

Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells.

Zhu B, Vemavarapu L, Thompson WJ, Strada SJ.

J Cell Biochem. 2005 Feb 1;94(2):336-50.

PMID:
15526282

Supplemental Content

Support Center